Search

everythinglearnresearchcommunity

for

Search:↓

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

New compounds can block testosterone effects in rats and might help treat conditions like prostate cancer and acne.

Liquorice may reduce testosterone and affect male reproductive organs, potentially helping treat conditions like prostate cancer.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Created microspheres show potential for safe and effective use in prostate artery embolization.

Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.

Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

Dutasteride works better than finasteride for preventing and treating prostate cancer.

D-004 may be a natural alternative to finasteride for treating enlarged prostate and male baldness.

Analog 23 is a promising compound for prostate cancer treatment.

Caesalpinia bonduc seed extracts may help treat enlarged prostate in rats.

Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.

Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.

Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.

Early hair loss may indicate future prostate issues.

Higher urethral PSA levels after prostate removal may be linked to more scalp hair loss and more PSA in urethral glands.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

Prostate cancer patients need early psychological and sexual support during radiotherapy to improve their quality of life.

Higher free testosterone levels can increase bone density and decrease body fat but may raise the risk of prostate cancer, hair loss, and benign prostate enlargement.

Leonuri Herba alkaloids may help treat hormone-induced enlarged prostate in rats.

Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.

A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

The Unani Pharmacopoeia-Based Formulation significantly improved symptoms of enlarged prostate in rats.